SUCLG2 Polyklonaler Antikörper

• Featured Product
• KD/KO Validated

SUCLG2 Polyklonal Antikörper für WB, IHC, IP, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus, Ratte

Anwendung

WB, IHC, IF, IP, ELISA

Konjugation

Unkonjugiert

Publikationen(5)

Rezensionen (1)

Kat-Nr. : 14240-1-AP

Synonyme

EC:6.2.1.4, G BETA, G-SCS, GTPSCS, GTP-specific succinyl-CoA synthetase subunit beta

---

• 

  WB analysis using 14240-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 14240-1-AP (SUCLG2 antibody) at dilution of 1:15000 incubated at room temperature for 1.5 hours.

• 

  IP experiment of mouse kidney using 14240-1-AP

  IP result of anti-SUCLG2 (IP:14240-1-AP, 4ug; Detection:14240-1-AP 1:600) with mouse kidney tissue lysate 4800ug.

• 

  IHC staining of human colon cancer using 14240-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 14240-1-AP (SUCLG2 antibody) at dilution of 1:500 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon cancer using 14240-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 14240-1-AP (SUCLG2 antibody) at dilution of 1:500 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of mouse kidney using 14240-1-AP

  Immunohistochemical analysis of paraffin-embedded mouse kidney tissue slide using 14240-1-AP (SUCLG2 antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human gliomas using 14240-1-AP

  Immunohistochemical analysis of paraffin-embedded human gliomas slide using 14240-1-AP (SUCLG2 Antibody) at dilution of 1:25.

• 

  IHC staining of human gliomas using 14240-1-AP

  Immunohistochemical analysis of paraffin-embedded human gliomas slide using 14240-1-AP (SUCLG2 Antibody) at dilution of 1:25.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: COLO 320-Zellen, HepG2-Zellen, Mauslebergewebe, Rattenlebergewebe
• Erfolgreiche IP: Mausnierengewebe
• Erfolgreiche Detektion in IHC: humanes Kolonkarzinomgewebe, humanes Gliomgewebe, Mausnierengewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:5000-1:50000
• Immunpräzipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
• Immunhistochemie (IHC): IHC : 1:250-1:1000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• KD/KO: See 1 publications below
• WB: See 4 publications below
• IHC: See 2 publications below
• IF: See 1 publications below
• IP: See 1 publications below

Produktinformation

14240-1-AP bindet in WB, IHC, IF, IP, ELISA SUCLG2 und zeigt Reaktivität mit human, Maus, Ratten

• Getestete Reaktivität: human, Maus, Ratte
• In Publikationen genannte Reaktivität: human, Ratte
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Polyklonal
• Typ: Antikörper
• Immunogen: SUCLG2 fusion protein Ag5495
• Vollständiger Name: succinate-CoA ligase, GDP-forming, beta subunit
• Berechnetes Molekulargewicht: 47 kDa
• Beobachtetes Molekulargewicht: 47 kDa
• GenBank-Zugangsnummer: BC047024
• Gene symbol: SUCLG2
• Gene ID (NCBI): 8801
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Antigen-Affinitätsreinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

SUCLG2, encodes a GTP-specific beta subunit of succinyl-CoA synthetase. Succinyl-CoA synthetase catalyzes the reversible reaction involving the formation of succinyl-CoA and succinate. The deficiency of SUCLG2 represents an encephalomyopathic form of mtDNA depletion syndromes (PMID:30470562). Mutated SUCLG1 causes mislocalization of SUCLG2 protein, morphological alterations of mitochondria and an early-onset severe neurometabolic disorder. SUCLG2 is mainly expressed in liver, kidney, heart (PMID: 9765291).

Publikationen

Species	Application	Title
human	WB,IP,IHC,IF	Adv Sci (Weinh); SUCLG2 Regulates Mitochondrial Dysfunction through Succinylation in Lung Adenocarcinoma; Authors - Qifan Hu
human	WB	Oncogene; Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion.; Authors - Susumu Kohno ; KO Validated
human	IHC	Clin Cancer Res; Biomarker identification and risk prediction model development for differentiated thyroid carcinoma lung metastasis based on primary lesion proteomics; Authors - Xiaoqi Peng
human	WB	Arthritis Rheumatol; Mitochondrial control of proteasomal Psmb5 drives the differentiation of tissue-resident memory T cells in patients with rheumatoid arthritis; Authors - Tong Wu
rat	WB	Biochim Biophys Acta Mol Basis Dis; SIRT5 mediated succinylation of SUCLA2 regulates TCA cycle dysfunction and mitochondrial damage in pancreatic acinar cells in acute pancreatitis; Authors - Wenbin Liu

Rezensionen

The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.

---

FH

Jun (Verified Customer) (05-08-2025)

Works well for WB, IP and IF

• Applications: Western Blot, Immunoprecipitation
• Primary Antibody Dilution: 1:1000 for WB; 1ug for IP
• Cell Tissue Type: C2C12 cells